The Lynx Group

Julie M. Vose, MD, MBA

Authored Items

Stakeholder’s Perspective: Physician Considerations

December 2012, Vol 4 No 1 - Uncategorized

Bendamustine has an interesting history that spans more than 50 years. Bendamustine was first synthesized in the early 1960s in the former East Germany. It was first used to treat multiple myeloma and was subsequently extended to patients with chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. Unfortunate­ly, [ Read More ]

Sign me up!